Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
89% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. ROSG: No Debt )
ROSG' s 10-Year Cash to Debt Range
Min: 0.77   Max: No Debt
Current: No Debt

Equity to Asset 0.95
ROSG's Equity to Asset is ranked higher than
99% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. ROSG: 0.95 )
ROSG' s 10-Year Equity to Asset Range
Min: -0.27   Max: 0.95
Current: 0.95

-0.27
0.95
F-Score: 4
Z-Score: 11.69
M-Score: 1.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4112.94
ROSG's Operating margin (%) is ranked lower than
55% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ROSG: -4112.94 )
ROSG' s 10-Year Operating margin (%) Range
Min: -9864.67   Max: -4112.94
Current: -4112.94

-9864.67
-4112.94
Net-margin (%) -5202.49
ROSG's Net-margin (%) is ranked lower than
55% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. ROSG: -5202.49 )
ROSG' s 10-Year Net-margin (%) Range
Min: -11003.33   Max: -5202.49
Current: -5202.49

-11003.33
-5202.49
ROE (%) -33.84
ROSG's ROE (%) is ranked higher than
53% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ROSG: -33.84 )
ROSG' s 10-Year ROE (%) Range
Min: -241.23   Max: -33.84
Current: -33.84

-241.23
-33.84
ROA (%) -32.15
ROSG's ROA (%) is ranked higher than
52% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. ROSG: -32.15 )
ROSG' s 10-Year ROA (%) Range
Min: -432   Max: -32.15
Current: -32.15

-432
-32.15
ROC (Joel Greenblatt) (%) -1514.10
ROSG's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. ROSG: -1514.10 )
ROSG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1514.1   Max: -838.2
Current: -1514.1

-1514.1
-838.2
Revenue Growth (%) -57.70
ROSG's Revenue Growth (%) is ranked higher than
53% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. ROSG: -57.70 )
ROSG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -57.7
Current: -57.7

EBITDA Growth (%) -67.10
ROSG's EBITDA Growth (%) is ranked lower than
51% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ROSG: -67.10 )
ROSG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -4.6
Current: -67.1

EPS Growth (%) -66.80
ROSG's EPS Growth (%) is ranked lower than
54% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ROSG: -66.80 )
ROSG' s 10-Year EPS Growth (%) Range
Min: -66.8   Max: 45.9
Current: -66.8

-66.8
45.9
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ROSG



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.10
ROSG's P/B is ranked higher than
93% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. ROSG: 1.10 )
ROSG' s 10-Year P/B Range
Min: 0.73   Max: 4.84
Current: 1.1

0.73
4.84
P/S 90.09
ROSG's P/S is ranked lower than
86% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. ROSG: 90.09 )
ROSG' s 10-Year P/S Range
Min: 3.33   Max: 209.09
Current: 90.09

3.33
209.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.20
ROSG's Price/Net Cash is ranked higher than
97% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. ROSG: 1.20 )
ROSG' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 7.58
Current: 1.2

1.31
7.58
Price/Net Current Asset Value 1.20
ROSG's Price/Net Current Asset Value is ranked higher than
99% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. ROSG: 1.20 )
ROSG' s 10-Year Price/Net Current Asset Value Range
Min: 1.31   Max: 7
Current: 1.2

1.31
7
Price/Tangible Book 1.10
ROSG's Price/Tangible Book is ranked higher than
95% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ROSG: 1.10 )
ROSG' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 3.68
Current: 1.1

1.02
3.68
Price/Median PS Value 1.20
ROSG's Price/Median PS Value is ranked higher than
64% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ROSG: 1.20 )
ROSG' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 2.48
Current: 1.2

0.21
2.48
Earnings Yield (Greenblatt) 2543.50
ROSG's Earnings Yield (Greenblatt) is ranked higher than
98% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. ROSG: 2543.50 )
ROSG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 5877
Current: 2543.5

0
5877
Forward Rate of Return (Yacktman) -826.13
ROSG's Forward Rate of Return (Yacktman) is ranked lower than
56% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. ROSG: -826.13 )
ROSG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -826.13

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RQ1.Germany
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide